Continuing Trastuzumab After Progression Shows Promise in HER2+ Gastric/GEJ Cancer
Continuing trastuzumab (Herceptin)-containing therapy beyond progression led to…
Browsing Tag
HER2
Dendritic Cell Vaccine Before Surgery Promising in HER2+ Breast Cancer
At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported on a…
Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
CHICAGO -- An "adaptive response" treatment strategy identified a subset of patients with HER2-positive early…
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in…
<!-- Name:DistributionId Value:1000802689 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM…
<!-- Name:DistributionId Value:1000802689 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
FDA Panel Gives Thumbs Down to Oral Drug for NSCLC With Rare HER2 Mutations
An FDA advisory committee decided that the clinical benefits of the multitargeted tyrosine…
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of…
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA)…
Adding Opdivo in First-Line Shows Promise in HER2+ Esophagogastric Cancer
A combination of the PD-1 inhibitor nivolumab (Opdivo) plus trastuzumab and chemotherapy…
A potentially more effective treatment for HER2 mutant metastatic breast cancer
Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable. Looking to better understand the underlying cause of this variation, a…
Black Diamond Therapeutics Announces Publication of New Computational and Functional…
- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine - CAMBRIDGE, Mass. and NEW YORK, May 12,…